User menu

Activities of antibiotic combinations against resistant strains of Pseudomonas aeruginosa in a model of infected THP-1 monocytes

Bibliographic reference Buyck, Julien ; Tulkens, Paul M. ; Van Bambeke, Françoise. Activities of antibiotic combinations against resistant strains of Pseudomonas aeruginosa in a model of infected THP-1 monocytes. In: Antimicrobial Agents and Chemotherapy, Vol. 59, no. 1, p. 258-268 (2015)
Permanent URL
  1. Sun Hsin-Yun, Fujitani Shigeki, Quintiliani Richard, Yu Victor L., Pneumonia Due to Pseudomonas aeruginosa, 10.1378/chest.10-0167
  2. Fish D. N., Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs, 10.1093/jac/dkf211
  3. McGrath B J, Lamp K C, Rybak M J, Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model., 10.1128/aac.37.9.1931
  4. Cappelletty D. M., Kang S. L., Palmer S. M., Rybak M. J., Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model, 10.1128/aac.39.8.1797
  5. Bergen P. J., Tsuji B. T., Bulitta J. B., Forrest A., Jacob J., Sidjabat H. E., Paterson D. L., Nation R. L., Li J., Synergistic Killing of Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula by Colistin Combined with Doripenem in an In Vitro Pharmacokinetic/Pharmacodynamic Model, 10.1128/aac.05298-11
  6. Bergen P. J., Forrest A., Bulitta J. B., Tsuji B. T., Sidjabat H. E., Paterson D. L., Li J., Nation R. L., Clinically Relevant Plasma Concentrations of Colistin in Combination with Imipenem Enhance Pharmacodynamic Activity against Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula, 10.1128/aac.05028-11
  7. Gordon N. C., Png K., Wareham D. W., Potent Synergy and Sustained Bactericidal Activity of a Vancomycin-Colistin Combination versus Multidrug-Resistant Strains of Acinetobacter baumannii, 10.1128/aac.00922-10
  8. Miller M H, Feinstein S A, Chow R T, Early effects of beta-lactams on aminoglycoside uptake, bactericidal rates, and turbidimetrically measured growth inhibition in Pseudomonas aeruginosa., 10.1128/aac.31.1.108
  9. Buyck J. M., Tulkens P. M., Van Bambeke F., Pharmacodynamic Evaluation of the Intracellular Activity of Antibiotics towards Pseudomonas aeruginosa PAO1 in a Model of THP-1 Human Monocytes, 10.1128/aac.02609-12
  10. Lovewell R. R., Patankar Y. R., Berwin B., Mechanisms of phagocytosis and host clearance of Pseudomonas aeruginosa, 10.1152/ajplung.00335.2013
  11. Schmiedl Andreas, Kerber-Momot Tanja, Munder Antje, Pabst Reinhard, Tschernig Thomas, Bacterial distribution in lung parenchyma early after pulmonary infection with Pseudomonas aeruginosa, 10.1007/s00441-010-1036-y
  12. Boyd Natalie, Nailor Michael D, Combination Antibiotic Therapy for Empiric and Definitive Treatment of Gram-Negative Infections: Insights from the Society of Infectious Diseases Pharmacists, 10.1592/phco.31.11.1073
  13. Engel Joanne, Eran Yonatan, Subversion of Mucosal Barrier Polarity by Pseudomonas Aeruginosa, 10.3389/fmicb.2011.00114
  14. Nguyen H. A., Denis O., Vergison A., Tulkens P. M., Struelens M. J., Van Bambeke F., Intracellular Activity of Antibiotics in a Model of Human THP-1 Macrophages Infected by a Staphylococcus aureus Small-Colony Variant Strain Isolated from a Cystic Fibrosis Patient: Study of Antibiotic Combinations, 10.1128/aac.01146-08
  15. Clinical and Laboratory Standard Institute, CLSI document MS100-S23 (2013)
  16. Barcia-Macay M., Seral C., Mingeot-Leclercq M.-P., Tulkens P. M., Van Bambeke F., Pharmacodynamic Evaluation of the Intracellular Activities of Antibiotics against Staphylococcus aureus in a Model of THP-1 Macrophages, 10.1128/aac.50.3.841-851.2006
  17. Eliopoulos, Antibiotics in laboratory medicine, 330 (1996)
  18. Bonapace Charles R., Bosso John A., Friedrich Lawrence V., White Roger L., Comparison of methods of interpretation of checkerboard synergy testing, 10.1016/s0732-8893(02)00473-x
  19. Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents, 10.1046/j.1469-0691.2000.00149.x
  20. Desbiolles N., Piroth L., Lequeu C., Neuwirth C., Portier H., Chavanet P., Fractional Maximal Effect Method for In Vitro Synergy between Amoxicillin and Ceftriaxone and between Vancomycin and Ceftriaxone against Enterococcus faecalis and Penicillin-Resistant Streptococcus pneumoniae, 10.1128/aac.45.12.3328-3333.2001
  21. Li R C, Schentag J J, Nix D E, The fractional maximal effect method: a new way to characterize the effect of antibiotic combinations and other nonlinear pharmacodynamic interactions., 10.1128/aac.37.3.523
  22. Hauser, Infect Immun, 66, 1413 (1998)
  23. Tamma P. D., Cosgrove S. E., Maragakis L. L., Combination Therapy for Treatment of Infections with Gram-Negative Bacteria, 10.1128/cmr.05041-11
  24. Fleiszig S. M. J., Arora S. K., Van R., Ramphal R., FlhA, a Component of the Flagellum Assembly Apparatus of Pseudomonas aeruginosa, Plays a Role in Internalization by Corneal Epithelial Cells, 10.1128/iai.69.8.4931-4937.2001
  25. Plotkowski, Infect Immun, 62, 5456 (1994)
  26. Kondo Akira, Hirakata Yoichi, Gotoh Naomasa, Fukushima Kazuko, Yanagihara Katsunori, Ohno Hideaki, Higashiyama Yasuhito, Miyazaki Yoshitugu, Nishide Kiyoharu, Node Manabu, Yamada Yasuaki, Kohno Shigeru, Kamihira Shimeru, Quorum Sensing System Lactones Do Not Increase Invasiveness of a MexAB-OprM Efflux Mutant but Do Play a Partial Role inPseudomonas aeruginosaInvasion, 10.1111/j.1348-0421.2006.tb03806.x
  27. Hirakata Yoichi, Srikumar Ramakrishnan, Poole Keith, Gotoh Naomasa, Suematsu Takashi, Kohno Shigeru, Kamihira Shimeru, Hancock Robert E. W., Speert David P., Multidrug Efflux Systems Play an Important Role in the Invasiveness ofPseudomonas aeruginosa, 10.1084/jem.20020005
  28. McClure Carol D., Schiller Neal L., Inhibition of Macrophage Phagocytosis by Pseudomonas aeruginosa Rhamnolipids In Vitro and In Vivo, 10.1007/s002849900084
  29. Garcia-Medina R., Dunne W. M., Singh P. K., Brody S. L., Pseudomonas aeruginosa Acquires Biofilm-Like Properties within Airway Epithelial Cells, 10.1128/iai.73.12.8298-8305.2005
  30. Vallet Coralie M., Marquez Béatrice, Ngabirano Eva, Lemaire Sandrine, Mingeot-Leclercq Marie-Paule, Tulkens Paul M., Van Bambeke Françoise, Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic/pharmacodynamic model of uninfected and infected macrophages, 10.1016/j.ijantimicag.2011.05.011
  31. Baudoux P., Bles N., Lemaire S., Mingeot-Leclercq M.-P., Tulkens P. M., Van Bambeke F., Combined effect of pH and concentration on the activities of gentamicin and oxacillin against Staphylococcus aureus in pharmacodynamic models of extracellular and intracellular infections, 10.1093/jac/dkl489
  32. Michael Julia, Barth Aline, Kloft Charlotte, Derendorf Hartmut, Pharmacodynamic In Vitro Models to Determine the Effect of Antibiotics, Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics (2014) ISBN:9780387756127 p.81-112, 10.1007/978-0-387-75613-4_5
  33. Hsieh Michael H., Yu Chen M., Yu Victor L., Chow Joseph W., Synergy assessed by checkerboard a critical analysis, 10.1016/0732-8893(93)90087-n
  34. Traugott Kristi A, Echevarria Kelly, Maxwell Pamela, Green Kay, Lewis James S, Monotherapy or Combination Therapy? ThePseudomonas aeruginosaConundrum, 10.1592/phco.31.6.598
  35. Bonapace Charles R, White Roger L, Friedrich Lawrence V, Bosso John A, Evaluation of antibiotic synergy against Acinetobacter baumannii: a comparison with Etest, time-kill, and checkerboard methods, 10.1016/s0732-8893(00)00163-2
  36. White, Antimicrob Agents Chemother, 40, 1914 (1996)
  37. Horrevorts A. M., de Ridder C. M., Poot M. C., de Jonge M. J. A., Degener J. E., Dzoljic-Danilovic G., Michel M. F., Kerrebijn K. F., Chequerboard titrations: the influence of the composition of serial dilutions of antibiotics on the fractional inhibitory concentration index and fractional bactericidal concentration index, 10.1093/jac/19.1.119
  38. Saiman Lisa, Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: ‘the motion for’, 10.1016/j.prrv.2007.04.006
  39. BERENBAUM MORRIS C., Minor synergy and antagonism may be clinically important, 10.1093/jac/19.2.271
  40. Mackay M.L, Milne K, Gould I.M, Comparison of methods for assessing synergic antibiotic interactions, 10.1016/s0924-8579(00)00149-7
  41. Chandrasekar P. H., Crane L. R., Bailey E. J., Comparison of the activity of antibiotic combinations in vitro with clinical outcome and resistance emergence in serious infection by Pseudomonas aeruginosa in non-neutropenic patients, 10.1093/jac/19.3.321
  42. Visalli, Antimicrob Agents Chemother, 42, 953 (1998)
  43. Eliopoulos G M, Eliopoulos C T, Antibiotic combinations: should they be tested?, 10.1128/cmr.1.2.139
  44. Vidaillac C., Benichou L., Duval R. E., In Vitro Synergy of Colistin Combinations against Colistin-Resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae Isolates, 10.1128/aac.05996-11
  45. Cappelletty, Antimicrob Agents Chemother, 40, 677 (1996)
  46. Kresken Michael, Körber-Irrgang Barbara, Läuffer Jörg, Decker-Burgard Sabine, Davies Todd, In vitro activities of ceftobiprole combined with amikacin or levofloxacin against Pseudomonas aeruginosa: evidence of a synergistic effect using time–kill methodology, 10.1016/j.ijantimicag.2011.01.028
  47. Meyer Richard D., Liu Susan, In vitro synergy studies with ciprofloxacin and selected beta-lactam agents and aminoglycosides against multidrug-resistant Pseudomonas aeruginosa, 10.1016/0732-8893(88)90017-x
  48. He Wendy, Kaniga Koné, Lynch A. Simon, Flamm Robert K., Davies Todd A., In vitro Etest synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the Etest method, 10.1016/j.diagmicrobio.2012.08.014
  49. Pankuch G. A., Lin G., Seifert H., Appelbaum P. C., Activity of Meropenem with and without Ciprofloxacin and Colistin against Pseudomonas aeruginosa and Acinetobacter baumannii, 10.1128/aac.00689-07
  50. Burgess David S, Nathisuwan Surakit, Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa, 10.1016/s0732-8893(02)00420-0